This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Atezolizumab for resected non-small cell lung cancer – adjuvant

< Back

Atezolizumab for resected non-small cell lung cancer – adjuvant


Cancer and Palliative Care

August 2020

Atezolizumab is in clinical development as an adjuvant treatment for resectable non-small cell lung cancer (NSCLC). An adjuvant treatment is an additional treatment given after primary treatment that aims to reduce risk of disease recurrence. Lung cancer is one of the most common and serious types of cancer and NSCLC is the most common type of lung cancer. Resectable cancer means that the cancer can be removed by surgery, which means the cancer is normally in earlier stages (I-II). Currently, patients with resectable NSCLC are offered chemotherapy following surgery; there are no immunotherapies (drugs that target the immune system) licensed for this patient group.
Atezolizumab is a type of protein called an antibody, which can bind to a protein called programmed death ligand 1 (PD-L1) to prevent it interacting with its target (PD-1). In doing so, atezolizumab helps immune cells kill cancer cells and is used to treat many different types of cancer that express PD-L1. Atezolizumab is administered intravenously (IV). If licensed, atezolizumab would offer an additional adjunctive treatment option for patients with resectable NSCLC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts